- Alpha-lipoic acid (ALA) shows modest, inconsistent effects on body weight in human trials — average losses of 1–2 kg over placebo in the best studies, which may not be clinically meaningful for most people.
- Most supporting evidence comes from short trials in people with obesity-related metabolic conditions, not healthy adults trying to lose weight.
- ALA is not a replacement for calorie deficit or exercise; any effect appears to be small and additive at best.
- High doses carry real risks and several important drug interactions — this supplement is not benign for everyone.
What the evidence shows
Alpha-lipoic acid has been studied for weight loss mainly because it improves insulin sensitivity and acts as a potent antioxidant — both mechanisms that are theoretically linked to metabolic rate and fat storage. The actual human trial data, however, is underwhelming.
A 2017 meta-analysis of randomized controlled trials found that ALA supplementation produced a statistically significant but very small reduction in body weight (weighted mean difference of about −1.27 kg) and BMI compared with placebo, with the effect being more pronounced in trials lasting longer than 12 weeks (Namazi et al., 2017). Sounds promising — until you notice that most of these trials enrolled people with type 2 diabetes, metabolic syndrome, or obesity, making the results hard to generalize to someone simply looking to shed a few kilograms.
An earlier pooled analysis reached similar conclusions: ALA reduced body weight by roughly 1.3 kg versus placebo, but the authors explicitly flagged the high heterogeneity across studies and the short follow-up periods as major limitations (Kucukgoncu et al., 2017). Heterogeneity here means the studies disagreed with each other more than you'd want to see — a sign we should interpret the pooled number cautiously.
Animal studies, particularly in rodents, show more dramatic appetite suppression and weight loss via ALA's action on the hypothalamus (Kim et al., 2004). Rodent data rarely translates cleanly to humans, and so far it hasn't here either.
Bottom line on evidence quality: The signal exists, but it's weak and mostly seen in people who already have metabolic dysfunction. For a lean or metabolically healthy individual, the evidence is essentially absent.
How it works (mechanism)
ALA is a naturally occurring compound that functions as a cofactor in mitochondrial energy metabolism. It has several properties relevant to body weight:
- Insulin sensitization: ALA activates AMP-activated protein kinase (AMPK), a cellular "fuel gauge" that promotes glucose uptake and fatty acid oxidation (Shen et al., 2008). Better insulin sensitivity can reduce fat storage driven by chronically elevated insulin.
- Appetite signaling: In animal models, ALA suppresses the hypothalamic enzyme AMPK, which paradoxically reduces food intake — the hypothalamus and peripheral tissues appear to respond in opposite directions (Kim et al., 2004).
- Antioxidant activity: Oxidative stress is associated with inflammation and impaired fat metabolism. ALA scavenges free radicals and regenerates other antioxidants (vitamins C and E, glutathione), potentially improving the metabolic environment.
These mechanisms are real and biologically plausible. The problem is that plausible mechanisms don't always produce meaningful clinical outcomes in humans, and the weight-loss trials reflect that gap.
Dose & timing if you try it
If you have discussed this with a healthcare provider and choose to try ALA for metabolic support, here is what the human trials used:
- Dose: 300–600 mg per day of R-ALA or racemic ALA (the R-form is the biologically active enantiomer; some researchers prefer it, though most trials used the racemic mixture).
- Timing: Taken on an empty stomach — roughly 30 minutes before meals — because food significantly reduces absorption (Gleiter et al., 1996).
- Duration: Most trials showing any effect ran 8–24 weeks. There is very little data beyond six months.
- Form: Oral supplements are widely available; IV ALA is used clinically for diabetic neuropathy but is not relevant for weight loss and should only be administered medically.
Keep expectations calibrated: even under trial conditions with motivated, monitored participants, the average extra loss versus placebo was around 1 kg. Real-world results are likely smaller.
Who should skip
- Pregnant or breastfeeding individuals: Safety data are insufficient; avoid supplemental doses.
- People taking thyroid medication (levothyroxine): ALA may reduce thyroid hormone levels and interfere with medication efficacy (Segermann et al., 1991). Discuss with your prescriber first.
- People on chemotherapy: ALA's antioxidant activity may theoretically interfere with oxidative mechanisms used by some cancer drugs — discuss with your oncologist.
- People with thiamine (vitamin B1) deficiency: ALA can worsen thiamine status at high doses; this is particularly relevant in people with alcohol use disorder.
- Those with hypoglycemia risk or on diabetes medications: Because ALA can lower blood sugar, combining it with insulin or sulfonylureas may cause additive hypoglycemia.
- Children and adolescents: No safety or efficacy data exist for this population.
Bottom line
Alpha-lipoic acid has a biologically coherent story for fat loss and a small, real signal in randomized trials — but "small and real" is doing a lot of work in that sentence. A 1–2 kg difference versus placebo over several months, primarily in people with metabolic disease, is not a compelling reason for a healthy adult to add another supplement and another expense to their routine.
If you have insulin resistance, metabolic syndrome, or type 2 diabetes and are already working with a clinician, ALA may offer modest complementary benefit and has reasonably well-characterized safety at 300–600 mg/day. For everyone else, the honest recommendation is to prioritize the interventions with far stronger evidence: a sustained calorie deficit, adequate protein, resistance training, and sleep. ALA is not a shortcut, and the current evidence does not support using it as one.
References
- Namazi N, Larijani B, Azadbakht L. (2017). Alpha-lipoic acid supplement in obesity treatment: A systematic review and meta-analysis of clinical trials. Clinical Nutrition, 37(2), 419–428.
- Kucukgoncu S, Zhou E, Lucas KB, Tek C. (2017). Alpha-lipoic acid (ALA) as a supplementation for weight loss: results from a meta-analysis of randomized controlled trials. Obesity Reviews, 18(5), 594–601.
- Kim MS, Park JY, Namkoong C, et al. (2004). Anti-obesity effects of alpha-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase. Nature Medicine, 10(7), 727–733.
- Shen QW, Zhu MJ, Tong J, Ren J, Du M. (2008). Ca2+/calmodulin-dependent protein kinase kinase is involved in AMP-activated protein kinase activation by alpha-lipoic acid in C2C12 myotubes. American Journal of Physiology — Cell Physiology, 295(5), C1216–C1221.
- Gleiter CH, Schug BS, Hermann R, et al. (1996). Influence of food intake on the bioavailability of thioctic acid enantiomers. European Journal of Clinical Pharmacology, 50(6), 513–514.
- Segermann J, Hotze A, Ulrich H, Rao GS. (1991). Effect of alpha-lipoic acid on the peripheral conversion of thyroxine to triiodothyronine. Arzneimittelforschung, 41(12), 1294–1298.